Analyst Soumit Roy from JonesTrading reiterated a Buy rating on Bicara Therapeutics Inc. and keeping the price target at $27.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy’s rating is based on several strategic advantages that Bicara Therapeutics Inc. holds over its competitors. Despite the competitive pressure from J&J’s recent data, Bicara’s combination of ficera with Keytruda offers a more favorable safety profile compared to J&J’s Rybrevant, which is combined with carboplatin and Keytruda. This combination in the first-line setting could lead to a worse safety profile, making Bicara’s approach more appealing.
Additionally, Bicara is approximately 12 months ahead of J&J in their trial timeline, with expected interim topline data from their Phase 2b/3 trial anticipated in 2027. Bicara’s focus on a chemo-sparing approach, particularly for patients with PD-L1 CPS ≥1, aligns with the preferred treatment strategy for a significant portion of HNSCC cases. These factors, combined with Bicara’s strategic trial design and timeline, contribute to the Buy rating given by Soumit Roy.
According to TipRanks, Roy is an analyst with an average return of -18.5% and a 24.80% success rate. Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and Cullinan Management.
In another report released on October 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.